{"id":"W6977432714","doi":"10.6084/m9.figshare.7806605","title":"Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC)","year":2019,"lang":"en","type":"article","venue":"Figshare","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Atezolizumab; Docetaxel; Nivolumab; Lung cancer; Clinical trial; Overall survival","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002357184,0.0008976998,0.001044528,0.0009812252,0.0007894262,0.001901945,0.001430225,0.001051768,0.003478515],"category_scores_gemma":[0.01142904,0.0004382822,0.002532023,0.001248339,0.0005947409,0.0007452009,0.0009297715,0.001425555,0.0001248185],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.08297773,"about_ca_system_score_gemma":0.07438389,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.9570965,"about_ca_topic_score_gemma":0.9538565,"domain_scores_codex":[0.9987256,0.000497664,0.00005678022,0.0001233004,0.0002935739,0.0003030267],"domain_scores_gemma":[0.9972166,0.001206064,0.0003307397,0.00006424737,0.0007528989,0.0004295194],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","study_design_scores_codex":[0.01753264,0.0008193844,0.06127215,0.00297947,0.00494812,0.0005978603,0.0002234853,0.7644736,0.001073493,0.01582569,0.01808344,0.1121707],"study_design_scores_gemma":[0.007886131,0.003506018,0.09016833,0.00180154,0.01021995,0.0006544026,0.0009496197,0.8531025,0.002251166,0.009105509,0.02004454,0.0003102957],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.906153,0.03213848,0.006087743,0.01269715,0.0003351012,0.00148547,0.02207084,0.0001914864,0.01884078],"genre_scores_gemma":[0.9906942,0.003081381,0.001899982,0.0004134576,0.00001836587,0.0001255552,0.002305139,0.00001566046,0.001446214],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.08297773,"threshold_uncertainty_score":0.6020484,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02878095576081491,"score_gpt":0.2970891464970044,"score_spread":0.2683081907361895,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}